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Summary
Background.  —  Karolinska  Rennes  (KaRen)  is  a  prospective  observational  study  to  characterize
heart failure  patients  with  preserved  ejection  fraction  (HFpEF)  and  to  identify  prognostic  factors
for long-term  mortality  and  morbidity.
Aims.  —  To  report  characteristics  and  echocardiography  at  entry  and  after  4—8  weeks  of  follow-
up.
Methods. —  Patients  were  included  following  an  acute  heart  failure  presentation  with  B-type
natriuretic  peptide  (BNP)  >  100  ng/L  or  N-terminal  pro-BNP  (NT-proBNP)  >  300  ng/L  and  left  ven-
tricular ejection  fraction  (LVEF)  >  45%.
Results.  —  The  mean  ±  SD  age  of  539  included  patients  was  77  ±  9  years  and  56%  were  women.
Patient history  included  hypertension  (78%),  atrial  tachyarrhythmia  (44%),  prior  heart  failure
(40%) and  anemia  (37%),  but  left  bundle  branch  block  was  rare  (3.8%).  Median  NT-proBNP  was
2448 ng/L  (n  =  438),  and  median  BNP  429  ng/L  (n  =  101).  Overall,  101  patients  did  not  return
for the  follow-up  visit,  including  13  patients  who  died  (2.4%).  Apart  from  older  age  (80  ±  9
vs. 76  ±  9  years;  P  =  0.006),  there  were  no  signiﬁcant  differences  in  baseline  characteristics
between  patients  who  did  and  did  not  return  for  follow-up.  Mean  LVEF  was  lower  at  entry  than
follow-up (56%  vs.  62%;  P  <  0.001).  At  follow-up,  mean  E/e′ was  12.9  ±  6.1,  left  atrial  volume
index 49.4  ±  17.8  mL/m2.  Mean  global  left  ventricular  longitudinal  strain  was  −14.6  ±  3.9%;  LV
mass index  was  126.6  ±  36.2  g/m2.
Conclusions.  —  Patients  in  KaRen  were  old  with  slight  female  dominance  and  hypertension  as
the most  prevalent  etiological  factor.  LVEF  was  preserved,  but  with  increased  LV  mass  and
depressed  LV  diastolic  and  longitudinal  systolic  functions.  Few  patients  had  signs  of  electrical
dyssynchrony  (ClinicalTrials.gov.—  NCT00774709).
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Karolinska  Rennes  (KaRen)  est  une  étude  observationnelle  prospective  menée  aﬁn
de caractériser  une  cohorte  de  patients  insufﬁsants  cardiaques  à  fraction  d’éjection  préservée
et aﬁn  d’identiﬁer  des  facteurs  pronostiques  de  morbi-mortalité.
Objectif.  —  Nous  rapportons  ici,  les  caractéristiques  à  l’inclusion  et  à  la  visite  de  4—8  semaines,
incluant les  données  échocardiographiques  analysées  au  centre  de  relecture.
Méthodes.  — Les  patients  sont  inclus  suite  à  une  hospitalisation  urgente  pour  une  insufﬁsance
cardiaque  clinique.  Les  natriurétique  peptide  de  type  B  (BNP)  >  100  ng/L  or  N-terminal  pro-
BNP (NT-proBNP)  >  300  ng/L  et  la  fraction  d’éjection  du  ventricule  gauche  >  45  %  étaient  des
pré-requis à  l’inclusion  dans  l’étude.
Résultats.  — Parmi  les  539  patients  inclus,  l’âge  était  de  77  ±  9  ans  avec  56  %  de  femmes.  Les
patients étaient  très  fréquemment  hypertendus  (78  %),  avec  une  histoire  d’arythmie  atriale
(44 %),  l’insufﬁsance  cardiaque  avant  (40  %)  et  l’anémie  (37  %),  mais  la  prévalence  du  bloc  de
branche gauche  était  limitée  (3,8  %).  Le  NT-proBNP  médian  était  de  2448  ng/L  (n  =  438)  et  le  BNP
médian 429  ng/L  (n  =  101).  Sur  l’ensemble,  101  patients  ne  sont  pas  revenus  à  la  visite  de  suivie
dont 13  (2,4  %)  qui  sont  décédés.  Outre  l’âge  plus  avancé  (80  ±  9  vs  76  ±  9  années  ;  p  =  0,006)
il n’y  a  avait  aucune  différence  dans  les  caractéristiques  des  patients  vus  en  urgence  puis  à
la visite  de  4—8  semaines.  La  fraction  d’éjection  du  ventricule  gauche  était  plus  basse  lors  de
l’admission  en  urgence  qu’à  la  visite  de  4—8  semaines  (56  %  vs  62  %  ;  p  <  0,001).  À  4—8  semaines,
le rapport  E/e′ était  de  12,9  ±  6,1,  le  volume  de  l’oreillette  gauche  de  49,4  ±  17,8  mL/m2.
Le strain  global  longitudinal  était  de  −14,6  ±  3,9  %  et  a  masse  ventriculaire  gauche  était  de
126,6 ±  36,2  g/m2.
Conclusions.  —  Les  patients  inclus  dans  KaRen  sont  surtout  des  femmes  âgées  et  hypertendues.
La fraction  d’éjection  du  ventricule  gauche  est  préservée  avec  une  augmentation  de  la  masse
ventriculaire,  une  altération  de  la  fonction  diastolique  et  de  la  composante  longitudinale
de la  fonction  systolique.  L’asynchronisme  électrique  est  peu  fréquent  (ClinicalTrials.gov.—
NCT00774709).
 Tou
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In  recent  years,  heart  failure  with  preserved  ejection
fraction  (HFpEF)  has  been  increasingly  recognized  as  a
w
e
ss  droits  réservés.
athophysiological  entity  [1]. The  proportion  of  patients
ith  heart  failure  with  HFpEF  is  about  50%  of  the  gen-
ral  heart  failure  population  [2—4]. In  epidemiological
urveys,  the  prognosis  of  HFpEF  is  nearly  as  poor  as  for
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were  re-assessed  at  the  4—8-week  visit.  Apart  from  older14  
eart  failure  with  reduced  ejection  fraction  (HFrEF)  [5—8].
espite  extensive  efforts  to  characterize  HFpEF  [9]  and  sev-
ral  randomized  therapeutic  trials,  little  is  known  about
he  clinical  course  and  treatment  options  for  this  condition.
uidelines  are  therefore  still  restricted  to  modifying  the  risk
actors  predominant  in  HFpEF,  such  as  to  obtain  strict  con-
rol  of  blood  pressure  or  to  treat  symptoms  of  congestion
ith  diuretics  [10].
Current  guidelines  highlight  the  importance  of  additional
bjective  criteria  to  signs  and  symptoms  and  preserved  or
ormal  ejection  fraction  for  the  diagnosis  of  HFpEF  [9—11].
hese  criteria  include  normal  left  ventricular  volume,
ncreased  left  atrial  volume,  left  ventricular  hypertro-
hy  and/or  diastolic  dysfunction  and  natriuretic  peptides
12],  whereas  diagnostic  criteria  for  dyssynchrony  are  not
ncluded.  Little  is  known  about  the  role  of  electrical
nd  mechanical  dyssynchrony  in  HFpEF  [13,14].  A  typical
eft  bundle  branch  block  (LBBB)  was  found  in  14.4%  of
atients  included  in  CHARM-Preserved  [15]  and  8.1%  in  I-
RESERVE  [16].  In  ischemic  HFpEF,  it  has  been  demonstrated
hat  both  left  ventricular  diastolic  and  atrial  mechanical
yssynchrony  may  impair  diastolic  function  [17]. It  has
herefore  been  suggested  that  dyssynchrony  may  contribute
o  the  pathophysiology  of  HFpEF,  warranting  the  need  for
 prospective  study  to  analyse  the  importance  of  these
actors  [17,18].
To  further  characterize  HFpEF  patients  and  to  look  for
ew  therapeutic  options  in  these  patients,  we  conducted  a
rospective  registry  study  of  HFpEF  patients  admitted  for  an
cute  heart  failure  exacerbation  in  Sweden  and  France  —  the
arolinska  Rennes  (KaRen)  study  [19].  The  aim  of  this  report
s  to  describe  and  compare  the  clinical  and  basic  echocar-
iographic  characteristics  of  the  study  populations  at  acute
resentation  and  at  4—8-week  follow-up.
ethods
he  rationale  and  design  of  the  KaRen  study  have  previously
een  published  [19].  Brieﬂy,  KaRen  is  a  prospective,  multi-
entre,  international,  observational  study  with  the  primary
bjective  to  determine  whether  electrical  or  mechani-
al  dyssynchrony  independently  affects  the  prognosis.  The
resent  work  sought  to  characterize  the  HFpEF  patients
ncluded  in  KaRen  according  to  their  main  clinical,  electro-
ardiographic  (ECG)  and  echocardiographic  characteristics.
atients  were  included  in  KaRen  between  1  May  2007  and
 December  2011  in  10  French  and  three  Swedish  univer-
ity  hospitals.  Details  on  inclusion  and  exclusion  criteria
ave  been  published  [19].  Patients  were  recruited  con-
ecutively  as  far  as  was  possible.  We  aimed  to  identify
t  least  400  patients  seeking  medical  attention  in  the
mergency  department  with  clinical  signs  and  symptoms
f  heart  failure  according  to  the  Framingham  criteria
13].  A  left  ventricular  ejection  fraction  (LVEF)  ≥  45%  by
chocardiography  and  natriuretic  peptides  (B-type  natri-
retic  peptide  [BNP]  >  100  ng/L  or  N-terminal  pro-BNP
NT-proBNP]  >  300  ng/L)  were  also  required.  All  three  inclu-
ion  criteria  (clinical  heart  failure,  LVEF  and  peptides)  had
o  be  veriﬁed  within  72  hours  of  presentation.
Anemia  was  deﬁned  as  hemoglobin  <  120  g/L  in  women
nd  <  130  g/L  in  men,  and  renal  dysfunction  as  serum
m
s
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reatinine  >  120  mol/L  or  an  estimated  glomerular  ﬁltra-
ion  rate  (eGFR)  <  60  mL/min.  Coronary  artery  disease  was
eﬁned  as  a  history  of  acute  myocardial  infarction,  coronary
rtery  bypass  or  angioplasty  or  >  50%  coronary  artery  steno-
is  on  a  coronary  angiogram.  Clinical  heart  failure  signs  were
lassiﬁed  as  signs  of  left  heart  failure,  right  heart  failure  or
oth  [19].
Patients  who  presented  acutely  with  heart  failure  were
creened,  and  patients  were  included  based  on  inclusion
riteria  in  the  acute  state  including  conventional  assess-
ent  of  ejection  fraction,  but  with  no  detailed  analysis
f  other  parameters.  Patients  returned  to  a stable  state
with  or  without  hospitalization)  according  to  the  conven-
ional  treatment  decided  by  individual  investigators.  After
—8  weeks,  included  patients  returned  to  the  hospital  for
xhaustive  clinical,  ECG  and  biological  reassessment  and  a
etailed  echocardiographic  study.  These  half-day  visits  were
tringently  analysed  in  dedicated  core  centres.  Follow-up
as  continued  for  ≥  18  months.
In  this  report,  we  describe  the  clinical  and  basic
chocardiographic  characteristics  of  patients  in  KaRen  at
aseline  and  at  4—8-week  follow-up.  The  description  is
ased  on  cut-off  values  published  in  2007  in  a  consen-
us  paper  about  HFpEF  [9]  and  according  to  the  American
ociety  of  Echocardiography  (ASE)/European  Association
f  Echocardiography  (EAE)  recommendations  for  chamber
uantiﬁcation  in  echocardiography  [20].
tatistical analysis
ontinuous  variables  are  presented  as  means  ±  standard
eviations  (SDs)  and/or  medians  (interquartile  ranges
IQR]).  Categorical  variables  are  presented  as  counts  and
ercentages.
To  compare  the  means  of  measurements  performed  at
wo  time  points  (baseline  and  4—8  weeks),  we  used  Student’s
 test  to  produce  a  statistic  for  the  null  hypothesis  that  the
ean  difference  equals  zero.  All  P-values  are  two-sided  and
tatistical  signiﬁcance  was  set  at  0.05.  All  analyses  were  per-
ormed  using  SAS® 9.3  Statistical  Procedures  (SAS  Institute
nc.,  Cary,  NC,  USA).
esults
he  ﬂow  chart  of  the  KaRen  study  is  shown  on  Fig.  1. Patients
n  = 584)  were  considered  for  inclusion  in  KaRen  between
 May  2007  and  1  December  2011.  Of  these,  29  did  not
eet  inclusion  criteria  and  16  withdrew  consent.  Thus,  539
atients  were  enrolled  in  the  study  and  assessed  at  base-
ine.  Of  these,  470  patients  were  admitted  to  hospital  for
eart  failure  treatment  and  69  were  sent  home  after  treat-
ent  revision.  Thirteen  patients  (2.4%)  died  and  21  (3.9%)
ere  re-hospitalised  for  heart  failure  between  enrolment
nd  the  4—8-week  visit.  A  total  of  101  patients  did  not
eturn  for  the  4—8-week  follow-up  visit,  leaving  438  whoean  age  (80  ±  9  vs.  76  ±  9  years;  P  =  0.006),  there  were  no
tatistically  signiﬁcant  differences  in  baseline  characteris-
ics  between  patients  who  returned  for  the  follow-up  visit
nd  those  who  did  not.
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ollow-up.
Figure 2. Distribution of major and minor Framingham criteria
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aFigure 1. Flow chart of the study from enrolment to 4—8-week f
Characteristics at acute admission and
4—8 weeks
The  mean  age  of  the  539  patients  was  77  ±  9  years,  and
56%  were  women  (Table  1).  A  history  of  heart  failure  was
found  in  40%.  The  history  of  heart  failure  symptoms  revealed
that  80%  of  patients  had  been  New  York  Heart  Association
(NYHA)  class  I/II  before  the  exacerbation  of  acute  heart
failure,  but  at  admission,  most  patients  (90%)  were  NYHA
III/IV.  Mean  LVEF  at  admission  was  56  ±  7%,  and  303  (56%)
had  LVEF  >  55%.  At  admission,  456  patients  (85%)  had  ≥  two
major  and  83  (15%)  had  one  major  and  ≥  two  minor  Fra-
mingham  criteria  for  heart  failure.  Median  NT-proBNP  was
2448  ng/L  and  median  BNP  439  was  429  ng/L  (Table  1).  Mean
systolic  blood  pressure  was  150  ±  31  mmHg  and  median  [IQR]
heart  rate  was  80  [68—100]  bpm.  The  median  [IQR]  eGFR  was
61  [43—76]  mL/min.  Among  the  470  hospitalized  patients,
the  mean  length  of  hospital  stay  at  the  acute  heart  failure
admission  was  5  days  (range  0—58  days).  The  distributions
of  Framingham  criteria  of  heart  failure  at  index  hospital-
ization  and  at  4—8-week  follow-up  are  shown  on  Fig.  2.
Many  patients  still  had  clinical  symptoms  or  signs  of  heart
failure  at  the  4—8-week  visit,  e.g.  30%  of  the  population
still  had  peripheral  oedema  despite  4—8  weeks  of  dedicated
treatments.
ECG and echocardiographic measurements at
4—8 weeks
ECG
At  4—8  weeks,  244  were  classiﬁed  as  ‘‘no  atrial  arrhyth-
mia’’  out  of  378  (64.55%).  Conduction  disturbances  were
rare  among  these  patients,  with  only  28  out  of  244  (11.48%),
13.5%  having  a  long  PR  interval  (>  200  ms)  and  52  out  of  348
not  V-paced  patients  (14.94%)  having  a  QRS  width  >  120  ms
(Table  1).  Right  bundle  branch  block  (RBBB)  was  present  in
31  out  of  348  (8.91%)  and  LBBB  in  24  out  of  348  (6.90%).Left  ventricular  ejection  fraction
Table  2  contains  echocardiographic  characteristics  at
4—8  weeks.  LVEF  was  preserved,  but  was  signiﬁcantly  lower
t
4
f
(or heart failure at admission to the hospital and in a stable state
t 4—8-week follow-up.
t  baseline  than  at  the  4—8-week  visit  (56  ±  7%  vs.  62  ±  7%;
 <  0.001).  Left  ventricular  fractional  shortening  was  >  30%
or  most  patients  (207/356;  61%).  Left  ventricular  s’
as  >  7  cm/s  for  105/356  (30%).  Left  ventricular  global  lon-
itudinal  strain  (GLS)  was  <  −16%  for  139/356  (67%).
eft  ventricular  volumes
 total  of  218/356  patients  (63%)  had  a  left  ventricular
nd-diastolic  volume  ≤  97  mL/m2,  showing  no  signiﬁcant  left
entricular  enlargement  [9].
iastolic  function
ig.  3  highlights  the  importance  of  diastolic  dysfunction
nd  the  association  of  enlarged  left  atrium  and  persis-
′ ′ent  E/e >  12  at  4—8  weeks.  E/e >  15  was  only  found  at  the
—8-week  visit  for  94/356  patients  (28%),  but  diastolic  dys-
unction  was  severe  as  e’  was  <  11  cm/s  for  310/356  patients
88%).  Also,  left  atrial  indexed  volume  was  >  32  mL/m2 (a
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Table  1  Main  clinical,  biological  and  ECG  characteristics  at  admission  for  acute  heart  failure  and  after  4—8  weeks  of
conventional  therapy  in  all  patients.
At  admission
(n =  539)
At  4—8-week  visit
(n =  438)
Age  (years)  77  ±  9  —
Women  303  (56)  —
Hypertension  419  (78)  —
Prior  heart  failure 216  (40) —
Prior  stroke  56  (10)  —
Coronary  artery  disease  158  (29)  —
Prior  myocardial  infarction  77  (15)  —
Valvular  heart  disease  74  (14)  —
Diabetes  161  (30)  —
Renal  dysfunction  146  (27)  —
Anemia  202  (37)  —
COPD  73  (14)  —
NYHA  class  n  =  527
I  4  (0.5)  49  (12)
II  49  (9.5)  243  (62)
III  211  (40)  90  (23)
IV  263  (50)  10  (3.0)
Heart  failure  clinical  presentation
Biventricular  364  (69)  63  (35)
Isolated  LV  129  (24)  44  (25)
Isolated  RV  36  (7.0)  71  (40)
3rd  heart  sound  31  (6.0)  11  (3.0)
SBP  (mmHg)  150  ±  31  138  ±  24
DBP  (mmHg)  77  ±  19  73  ±  12
Pulse  pressure  (mm  Hg),  median  [IQR] 70  [55—90] 65  [50—78]
Heart  rate  (bpm),  median  [IQR]  80  [68—100]  68  [60—76]
Weight  (kg)  79  ±  20  78  ±  19
BMI  (kg/m2)  29  ±  6  29  ±  6
NT-proBNP  (ng/L)a,  median  [IQR]  2448  [1290—4790]  1409  [517—2635]
BNP  (ng/L)b,  median  [IQR]  429  [229—805]  277  [136—570]
Hemoglobin  (g/L)  123  ±  19  125  ±  17
eGFR  (mL/min),  median  [IQR]  61  [43—76]  60  [42—77]
Atrial  arrhythmia  218  (44)  171  (39)
PR  interval  >  200  ms 26 (11)  25  (14)
QRS  duration  >  120  ms  69  (15)  57  (16)
LBBB  16  (3.5)  14  (3.8)
RBBB  35  (7.6)  24  (6.6)
Paced  V  rhythm  35  (7.1)  29  (7.3)
Data are mean ± standard deviation or n (%) unless otherwise speciﬁed. IQR: interquartile range; BMI: body mass index; BNP: B-type
natriuretic peptide; COPD: chronic obstructive pulmonary disease; DBP: diastolic blood pressure; ECG: electrocardiogram; eGFR:
estimated glomerular ﬁltration rate; LBBB: left bundle branch block; LV: left ventricular; NT-proBNP: or N-terminal pro-B-type
natriuretic peptide; NYHA: New York Heart Association; RBBB: right bundle branch block; RV: right ventricular; SBP: systolic blood
pressure.
a n = 434.
b n = 101.
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Table  2  Echocardiographic  characteristics.
4—8-week  visit
(n  =  356)
Mean  ±  SD  Median  (range)
LVEF  (%)  62  ±  7  63  (45—80)
LVEDV  (mL/m2)  92  ±  30  86  (33—211)
LVESV  (mL/m2)  35  ±  15  33  (8—95)
LA  volume  (mL/m2)  49  ±  18  46  (4-158)
Inter-ventricular  septal  thickness  (mm)  11.6  ±  2.3  11  (6—21)
LV  end-diastolic  diameter  (mm) 47.3  ±  6.3 47 (26—65)
LV  end-systolic  diameter  (mm) 32.1  ±  6.6 32 (12—53)
LV  fractional  shortening  (%) 32.7  ±  7.9 33 (12—62)
LV  mass  indexed  (g/m2)  126.6  ±  36.2  123  (40—266)
Stroke  volume  (mL/m2)  31  ±  8  29  (4—60)
LA  diameter  (mm)  45.5  ±  6.6  45  (23—71)
Indexed  LA  volume  (mL/m2)  49.4  ±  17.8  46.6  (14.0—158.2)
RA  area  (cm2)  20.5  ±  5.9  20  (8—55)
Cardiac  output  (mL/m2)  4.8  ±  1.5  4.6  (1.6—12.0)
Tricuspid  regurgitation  (m/s)  2.9  ±  0.6  2.8  (1.0—4.7)
E-wave  deceleration  time  (ms)  194  ±  75  184  (54—687)
E/A  1.8  ±  1.3  1.2  (0.3—8.3)
Mitral  inﬂow  duration/RR  interval  (%)  51  ±  12  51  (11—57)
e′ (cm/s)  (average  septal  an  lateral  part  of  mitral  annulus)  7.9  ±  2.6  7.5  (2.5—18.0)
E/e′ 12.9  ±  6.1  11.3  (2.5—40.6)
LVPEI  (ms)  84  ±  31  79  (5—360)
Inter  V  time  delay  (ms)  19  ±  16  14  (0—102)
LV  s′ (cm/s)  (average  septal  and  lateral  side  of  mitral  annulus)  7.3  ±  2.0  7  (3—15)
Time  difference  between  s′ septal  and  lateral  side  of  mitral
annulus  (ms)
35 ±  58  19  (−94,  301)
Delay  between  longitudinal  strain  peaks  from  the  lateral  and
the  septal  LV  walls  (ms)
18 ±  192  27  (−295,  332)
Global  longitudinal  strain  (%) −14.6 ± 3.9 −15 (−25 to  —3)
RV  fractional  shortening  (%) 19.4 ±  5.6 18.4  (9.4—39.3)
TAPSE  (mm)  17  ±  6  17  (4—31)
RV  s′ (cm/s)  11  ±  3  11  (3—20)
RV  strain  (%)  −19  ±  5  −19  (−35—27)
LA: left atrial; LV: left ventricular; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left
ventricular end-systolic volume; LVPEI: left ventricular pre-ejection interval; RA: right atrial; RV: right ventricular; SD: standard
deviation; TAPSE; tricuspid annular plane systolic excursion.
l
4
4
i
r
c
o
n
D
K
apredictor  of  cardiovascular  events  [9])  for  220/356  patients
(85%).
Left  ventricular  hypertrophy
Signs  of  left  ventricular  hypertrophy  were  found  on  ECG  in
a  minority  of  patients  (25/356;  5%),  but  echocardiography
showed  left  ventricular  hypertrophy  in  39%  of  patients.
Medication
The  prescription  rates  of  angiotensin-converting-enzyme
inhibitors  (ACEi)/angiotensin  II  receptor  blockers  (ARBs)  and
beta-blockers  were  60%  and  64%,  respectively,  at  admission
and  increased  by  around  10%  at  discharge  (Table  3).  The
prescription  rate  of  K+-sparing  diuretics  was  low,  but  dou-
bled  from  10%  to  22%  between  admission  and  4—8-week
follow-up.  More  than  half  of  the  patients  (60%)  were  on
s
T
a
loop  diuretics  at  admission,  and  this  increased  to  83%  at
—8  weeks,  with  a  median  (range)  dose  of  furosemide  at
—8  of  40  (20—1000)  mg/day.  Diuretics  were  discontinued
n  29  patients  after  enrolment,  whereas  43  patients  never
eceived  diuretics.  Conversely,  the  prescription  rate  of  cal-
ium  antagonists  (34%  at  admission)  decreased  somewhat
ver  time.  Anti-arrhythmic  drugs  were  used  in  15%  and  did
ot  increase  over  time.
iscussion
aRen  prospectively  included  a  population  of  HFpEF  patients
s  strictly  deﬁned  by  validated  Framingham  criteria,  pre-
erved  ejection  fraction  and  elevated  natriuretic  peptides.
he  short-term  mortality  was  low.  The  populations  at  entry
nd  4—8-week  follow-up  were  generally  similar,  except  for
ower  LVEF  at  study  entry.  After  4—8  weeks  of  dedicated
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Figure 3. A. Repartition of the individual values of GLS (left) and LV s’ (right) pulsed tissue Doppler values averaged from the measurement
at the mitral annulus septal and lateral sides. B. Repartition of the individual values of TAPSE (left) and RV s’ (center) (pulse tissue Doppler
r  the t
m RV; r
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fecorded at the tricuspid annulus, free wall side); and repartition of
edian values. GLS: global longitudinal strain; LV: left ventricular; 
reatment,  an  important  proportion  of  patients  still  showed
ymptoms  and  signs  of  heart  failure.  Aetiological  factors
nd  co-morbid  conditions  were  as  previously  described  for
FpEF  patients  [2—5],  with  a  high  proportion  of  female
ender,  hypertension  and  atrial  tachyarrhythmias.  Diagnos-
ic  criteria  for  HFpEF  left  ventricular  diastolic  dysfunction,
d
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Table  3  Medication  at  discharge  from  acute  admission  and  af
who  attended  4—8-week  follow-up.
At  admission
(n =  438)
ACEi/ARB  264  (60)  
Beta-blockers  284  (64)  
Digoxin  31  (7)  
Diuretics  264  (60)  
K+-sparing  diuretics  45  (10)  
Nitrates  17  (4)  
Calcium  antagonists  152  (34)  
Anti-arrhythmic  drugs  68  (15)  
Antiplatelets  179  (41)  
Warfarin  179  (40)  
ACEi: angiotensin-converting-enzyme inhibitor; ARB: angiotensin II recricuspid regurgitation peak velocities (right). Horizontal lines show
ight ventricular; TAPSE; tricuspid annular plane systolic excursion.
ccording  to  guideline  criteria,  were  frequently  observed,
nd  left  ventricular  systolic  dysfunctions  were  frequently
ound  despite  LVEF  >  45%.  Also,  dyssynchrony  as  classically
eﬁned  by  bundle  branch  block  or  atrioventricular  conduc-
ion  abnormalities  does  not  seem  to  be  a  strong  determinant
n  HFpEF.
ter  4—8  weeks  of  conventional  therapy  in  the  438  patients
At  discharge
(n =  438)
4—8  weeks
(n  =  438)
313  (73)  296  (68)
319  (74)  293  (80)
40  (9)  33  (8)
378  (88)  361  (82)
64  (15)  97  (22)
24  (6)  15  (3)
133  (31)  119  (28)
89  (18)  67  (15)
167  (39)  142  (33)
228  (53)  222  (51)
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the  4—8-week  echocardiography  had  to  be  fully  digitallyBaseline  characteristics  of  patients  in  KaRen  
Baseline characteristics in KaRen and clinical
presentation
The  KaRen  patients  diagnosed  with  HFpEF  are  differ-
ent  from  patients  with  HFrEF,  with  a  rather  high  female
representation,  high  mean  weight  and  a  high  proportion
of  underlying  hypertension.  The  mean  LVEF  at  admission
(56%)  was  comparable  to  patients  in  the  OPTIMIZE-HF  reg-
istry  [21],  but  KaRen  patients  more  often  had  a  history
of  atrial  ﬁbrillation  [22].  Mean  age  was  high  (77  ±  9  years)
and  underlying  diabetes,  coronary  artery  disease  and  COPD
were  reported  less  often  than  in  most  previous  studies
[15—17,22].  Patients  included  in  KaRen  are  thus  slightly  dif-
ferent  from  patients  previously  described,  mainly  in  the
United  States  of  America.  Only  40%  of  KaRen  patients  had  a
prior  heart  failure  admission,  which  is  much  lower  than  in
registries  such  as  ADHERE  [23]  (63%)  and  CHARM-Preserved
[24]  (69%)  and  may  reﬂect  the  unselective  nature  of  our
study.  This  may  in  part  also  account  for  the  low  short-
term  mortality.  The  patient  proﬁle  in  KaRen  was  driven
by  the  fact  that  patients  were  admitted  only  in  large
hospitals  and  their  dominant  symptoms  were  linked  to
heart  failure.  They  were  admitted  and  examined  in  car-
diology  units.  The  mean  blood  pressure  of  150/77  mmHg
in  KaRen  is  comparable  to  ADHERE  [23]  (152/79  mmHg).
In  KaRen  and  ADHERE,  patients  were  included  after  an
acute  decompensation  (main  diagnosis).  In  OPTIMIZE-HF,
blood  pressure  was  lower  (129/72  mmHg),  but  patients  were
recruited  according  to  whether  they  had  signs  or  symp-
toms  of  heart  failure  as  a  primary  discharge  diagnosis
[14,25,26].
There  are  several  characteristics  and  clinical  presenta-
tions  of  HFpEF  that  are  not  necessarily  different  from  HFrEF.
In  spite  of  different  baseline  characteristics,  the  acute  clin-
ical  presentation  in  KaRen  was  similar  to  HFpEF  and  HFrEF
patients  [22,26].  As  in  the  OPTMIZE-HF  registry  [14], 69%
of  patients  presented  with  signs  of  left  ventricular  and
right  ventricular  failure  and  only  24%  presented  with  iso-
lated  left  ventricular  failure.  Deﬁnitively,  it  is  not  possible
to  distinguish  HFrEF  and  HFpEF  patients  based  on  clinical
presentation  alone  [14,15].
It  is  known  that  about  50%  of  patients  with  HFrEF  or
HFpEF  are  discharged  from  hospital  with  residual  signs
of  congestion  [27].  We  did  not  measure  body  weight  at
the  time  of  discharge.  However,  weight  was  only  reduced
by  a  mean  of  1  kg  at  the  4—8-week  follow-up  compared
to  hospital  admission,  suggesting  insufﬁcient  treatment  of
congestion  at  the  acute  admission  in  spite  of  a  mean  hos-
pital  stay  of  5  days  and  relatively  high  usage  of  diuretics.
More  evidence  for  insufﬁcient  therapy  is  the  fact  the  NT-
proBNP  and  BNP  levels  remained  high  even  at  4—8  weeks.
It  is  natural  to  assume  that  one  of  the  reasons  for  this
insufﬁcient  improvement  is  a  lack  of  guideline-indicated
treatments  besides  diuretics  and  drugs  for  hypertension
[10].  However,  this  is  not  the  only  reason  since  HFrEF
patients,  despite  guidelines  for  highly  beneﬁcial  treatment,
have  the  same  proportion  of  insufﬁcient  improvements
[27].  According  to  the  treatments  prescribed  in  patients
included  in  KaRen,  beta-blockers,  diuretics,  aldosterone
antagonists  and  other  blockers  of  the  renin  angiotensin
system  were  prescribed  in  similar  proportions  to  previous
reports  [28].
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chocardiographic characteristics
eft  ventricular  ejection  fraction  >  45%  does  not  mean  that
here  is  no  anatomic  or  functional  reason  to  develop  signs
nd  symptoms  or  heart  failure  [14,29]. Most  patients  had
eft  ventricular  concentric  remodelling  or  increase  in  left
entricular  mass  with  an  abnormal  left  ventricular  longi-
udinal  function  (left  ventricular:  LV-s’  7.3  ±  2.0  cm/s  or
LS  —  14.6  ±  3.9%).  These  patients  had  also  diastolic  dys-
unction  (depressed  e’  7.9  ±  2.6  cm/s  and  large  left  atrium).
till,  after  4—8  weeks  of  dedicated  treatment,  a  large  num-
er  of  patients  kept  the  association  E/e′ >  12  and  enlarged
eft  atrium  (Fig.  3).  However,  these  abnormalities  of  the
ystolic  and  diastolic  functions  of  the  left  heart  were  not
bserved  in  every  patient.  In  I-PRESERVE,  the  left  atrium
as  normal  in  34%  of  the  population  and  diastolic  func-
ion  was  classiﬁed  as  normal  in  31%  [29]. These  left  heart
ysfunctions  are  frequently  associated  with  right  heart
bnormalities  that  might  also  be  more  obvious  than  any
eft  heart  remodelling  [30]. The  right  heart  longitudinal
unction  is  frequently  depressed  (RV  s′ 11  ±  3  cm/s;  RV
ongitudinal  strain—19  ±  5%,  TAPSE  17  ±  6  mm)  and  the  esti-
ated  pulmonary  pressure  after  4—8  weeks  of  treatment
f  the  congestion  remains  high  in  many  patients  (tricuspid
egurgitation  2.9  ±  0.6  m/s).  The  prevalence  of  electrical
nd  mechanical  dyssynchrony  was  low  (LBBB  3.8%).  Nev-
rtheless,  new  sophisticated  and,  very  probably,  more
ppropriate  tools  to  characterize  mechanical  dyssynchrony
like  strain  peaks  dispersion)  should  very  probably  be  looked
or  in  this  population  [31]. Also,  it  would  be  relevant  to
easure  the  strain  delay  index,  which  has  been  elegantly
emonstrated  as  clearly  abnormal  in  38  patients  with  HFpEF
32]. Further  work  is  thus  required  before  afﬁrming  that
he  majority  of  patients  included  in  KaRen  have  no  signiﬁ-
ant  mechanical  dyssynchrony  that  might  affect  myocardial
unction  efﬁciency  and  prognosis.
imitations
he  present  report  is  limited  to  the  assessment  of  HFpEF
atients  during  two  phases  of  their  disease:  at  admission  for
cute  decompensation  and  4—8  weeks  later  after  treatment
ptimization.  A  complete  and  analysable  echocardiographic
ecording  was  unfortunately  only  available  for  356/539
atients  (66%).  Despite  informed  consent  at  baseline,  these
6  did  not  return  to  the  hospital  for  their  scheduled  4—8-
eek  visit.  They  all  explained  that  they  felt  too  old  and
ependent  to  justify  any  further  displacement  to  the  hos-
ital.  It  was  evident  that  many  HFpEF  patients  did  not
omplain  between  acute  episodes  despite  the  presence  of
igns  and  symptoms.  They  were  considering  their  health
tatus  as  mainly  linked  to  their  age.  A  comparison  of  the
haracteristics  of  patients  who  had  an  echocardiography
ersus  those  who  did  not  showed  any  difference.  The  base-
ine  echocardiography  had  to  be  performed  within  the  ﬁrst
2  hours  after  admission,  but  did  not  have  to  be  digitally
ecorded  and  complete;  it  was  just  to  assess  LVEF.  Onlyecorded  and  re-interpreted  at  the  core  laboratory  for
chocardiography.  The  current  guidelines  deﬁne  LVEF  ≥  50%
s  abnormal  [10]. In  KaRen,  LVEF  was  45—49%  for  15%  of  the
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opulation,  the  others  have  as  required  by  current  guide-
ines,  a  LV  EF  ≥  50%.
onclusions
atients  in  KaRen  were  old  with  slight  female  dominance,
 high  rate  of  hypertension  and  much  co-morbidity.  LVEF
as  preserved  despite  depressed  left  ventricular  longitudi-
al  and  diastolic  functions.  Electric  dyssynchrony  does  not
eem  to  be  a  strong  determinant  in  HFpEF.  After  4—8  weeks
f  dedicated  treatment,  an  important  proportion  of  patients
till  showed  symptoms  and  signs  of  heart  failure.
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